ARS Pharmaceuticals, Inc. (SPRY) Deep Dive Video

ARS Pharmaceuticals offers asymmetric upside as neffy attempts to redefine anaphylaxis care, but the thesis depends on rapid commercial execution before cash burn, payer friction, litigation, or new needle-free rivals narrow the opportunity.